eMedicine Specialties > Physical Medicine and Rehabilitation > Myopathy

Corticosteroid-Induced Myopathy: Treatment & Medication

Author: Steve S Lim, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, St Clare's Hospital of Dover
Coauthor(s): Patrick M Foye, MD, FAAPMR, FAAEM, Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain Service (Tailbone Pain Service: www.TailboneDoctor.com), University of Medicine and Dentistry of New Jersey, New Jersey Medical School
Contributor Information and Disclosures

Updated: Sep 28, 2009

Treatment

Rehabilitation Program

Physical Therapy

Some literature suggests that aerobic exercises and resistance training may help to prevent weakness or reduce its severity. Although there are no definitive recommendations regarding therapy for steroid myopathy, it would seem reasonable to direct therapy to address the weakness and resulting impaired mobility. Range-of-motion exercises (either passive, active-assisted, or active, depending on the degree of weakness) and stretching exercises should be performed to prevent joint contractures. As a general rule, resistance exercises should be limited to muscles with greater than antigravity strength. Bed mobility, balance activities, transfer training, and gait training should be included to address decreased mobility. However, high intensity exercise should be avoided, because, according to some preliminary animal research models, it may be harmful.15

Occupational Therapy

Occupational therapy may focus on maximizing the patient's ability to independently perform activities of daily living. Training may include the use of assistive devices to enhance the patient's performance of self-care tasks, such as a balanced forearm orthosis to allow positioning of the upper arm in a manner that permits more independent feeding. Other adaptive equipment may include a raised toilet seat and similar devices that allow the patient to rise from a sitting position, and/or a motorized lift for ascending stairs.

Consultations

Any adjustment of a patient's corticosteroid medications should be coordinated with the physician who has been prescribing those agents. Given reports of respiratory muscle weakness causing respiratory impairments,7,16 consider consultation with a pulmonologist. Consultation with a neurologist can be considered for assistance with diagnosis and for the exclusion of other potential causes of weakness. A physiatrist can also be consulted for assistance with diagnosis and with the management of a therapy program.

Other Treatment

  • In cases of myopathy caused by long-term corticosteroid use, decreasing the corticosteroid dose to below a 30 mg/d threshold may result in resolution of muscle weakness. In patients in whom myopathy has resulted from a short course of high-dose corticosteroid use, partial or complete recovery has been reported following the discontinuation of steroid administration.16
  • Preliminary studies on rats suggest that creatine plays a part in the prophylaxis of steroid-induced myopathy. Further studies are needed to explore this possible treatment/prevention option.17

Medication

Various medications, including potassium supplements, phenytoin, vitamin E, and anabolic steroids, have been tried as potential treatments for steroid myopathy.5 None have been clearly shown to prevent or reverse muscle weakness induced by steroid myopathy. The main treatment recommendations for steroid myopathy are a decrease in the dose of steroid to below a threshold level or the discontinuation of the corticosteroid's use. Alternate-day dosing could also be considered.18 Another recommendation is that the currently administered steroid be exchanged for one that is not fluorinated.

More on Corticosteroid-Induced Myopathy

Overview: Corticosteroid-Induced Myopathy
Differential Diagnoses & Workup: Corticosteroid-Induced Myopathy
Treatment & Medication: Corticosteroid-Induced Myopathy
Follow-up: Corticosteroid-Induced Myopathy
References
Further Reading
[ CLOSE WINDOW ]

References

  1. Askari A, Vignos PJ Jr, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med. Oct 1976;61(4):485-92. [Medline].

  2. Yamaguchi M, Niimi A, Minakuchi M, et al. Corticosteroid-induced myopathy mimicking therapy-resistant asthma. Ann Allergy Asthma Immunol. Oct 2007;99(4):371-4. [Medline].

  3. Lacomis D, Smith TW, Chad DA. Acute myopathy and neuropathy in status asthmaticus: case report and literature review. Muscle Nerve. Jan 1993;16(1):84-90. [Medline].

  4. Inder WJ, Jang C, Obeyesekere VR, et al. Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1 - implications for steroid-induced myopathy. Clin Endocrinol (Oxf). Aug 4 2009;[Medline].

  5. Betters JL, Long JH, Howe KS, et al. Nitric oxide reverses prednisolone-induced inactivation of muscle satellite cells. Muscle Nerve. Feb 2008;37(2):203-9. [Medline].

  6. Kumar S. Steroid-induced myopathy following a single oral dose of prednisolone. Neurol India. Dec 2003;51(4):554-6. [Medline]. [Full Text].

  7. Dekhuijzen PN, Decramer M. Steroid-induced myopathy and its significance to respiratory disease: a known disease rediscovered. Eur Respir J. Sep 1992;5(8):997-1003. [Medline].

  8. Borba A, Guil D, Naveso G, et al. [Oral steroids effects on the respiratory muscles function in severe asthmatic patients.]. Rev Port Pneumol. Dec 2006;12(6 Suppl 1):39-40. [Medline].

  9. Stanton AE, Sellars C, Mackenzie K, et al. Perceived vocal morbidity in a problem asthma clinic. J Laryngol Otol. Jan 2009;123(1):96-102. [Medline].

  10. Afifi AK, Bergman RA, Harvey JC. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J. Oct 1968;123(4):158-73. [Medline].

  11. Danon MJ, Schliselfeld LH. Study of skeletal muscle glycogenolysis and glycolysis in chronic steroid myopathy, non-steroid histochemical type-2 fiber atrophy, and denervation. Clin Biochem. Jan 2007;40(1-2):46-51. [Medline].

  12. Dumitru D. Myopathies. In: Electrodiagnostic Medicine. San Antonio, Tex: University of Texas; 1995:1031-129.

  13. Hanson P, Dive A, Brucher JM, et al. Acute corticosteroid myopathy in intensive care patients. Muscle Nerve. Nov 1997;20(11):1371-80. [Medline].

  14. Ahlbeck K, Fredriksson K, Rooyackers O, et al. Signs of critical illness polyneuropathy and myopathy can be seen early in the ICU course. Acta Anaesthesiol Scand. Jul 2009;53(6):717-23. [Medline].

  15. Uchikawa K, Takahashi H, Hase K, et al. Strenuous exercise-induced alterations of muscle fiber cross-sectional area and fiber-type distribution in steroid myopathy rats. Am J Phys Med Rehabil. Feb 2008;87(2):126-33. [Medline].

  16. Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology. May 1997;48(5):1234-8. [Medline].

  17. Menezes LG, Sobreira C, Neder L, et al. Creatine supplementation attenuates corticosteroid-induced muscle wasting and impairment of exercise performance in rats. J Appl Physiol. Feb 2007;102(2):698-703. [Medline]. [Full Text].

  18. Hollister JR. The untoward effects of steroid treatment on the musculoskeletal system and what to do about them. J Asthma. 1992;29(6):363-8. [Medline].

[ CLOSE WINDOW ]

Keywords

corticosteroid-induced myopathy, myopathy, steroid, steroids, corticosteroid, corticosteroids, polymyositis, dermatomyositis, adrenal tumor, adrenal tumors, hydrocortisone, prednisone, triamcinolone, dexamethasone, steroid myopathy, acute steroid myopathy, chronic steroid myopathy, critical illness myopathy, excess endogenous corticosteroid production, excess exogenous corticosteroid production, asthma, steroid treatment for asthma, steroid treatment for polymyositis, steroid treatment for connective tissue disorders, steroid treatment for rheumatoid arthritis, fluorinated steroids, nonfluorinated steroids, prolonged administration of prednisone

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Steve S Lim, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, St Clare's Hospital of Dover
Steve S Lim, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation
Disclosure: Nothing to disclose.

Coauthor(s)

Patrick M Foye, MD, FAAPMR, FAAEM, Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain Service (Tailbone Pain Service: www.TailboneDoctor.com), University of Medicine and Dentistry of New Jersey, New Jersey Medical School
Patrick M Foye, MD, FAAPMR, FAAEM is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, Association of Academic Physiatrists, and International Spine Intervention Society
Disclosure: Nothing to disclose.

Medical Editor

Patrick J Potter, MD, FRCP(C), Associate Professor, Physical Medicine and Rehabilitation, The University of Western Ontario; Consulting Staff, Department of Physical Medicine and Rehabilitation, St Joseph's Health Care Centre
Patrick J Potter, MD, FRCP(C) is a member of the following medical societies: American Paraplegia Society, Canadian Association of Physical Medicine and Rehabilitation, Canadian Medical Association, College of Physicians and Surgeons of Ontario, Ontario Medical Association, and Royal College of Physicians and Surgeons of Canada
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Kat Kolaski, MD, Assistant Professor, Departments of Orthopedic Surgery and Pediatrics, Wake Forest University School of Medicine
Kat Kolaski, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine and American Academy of Physical Medicine and Rehabilitation
Disclosure: Nothing to disclose.

CME Editor

Kelly L Allen, MD, Regional Medical Director, IMX-Medical Management Services
Disclosure: Nothing to disclose.

Chief Editor

Denise I Campagnolo, MD, MS, Director of Multiple Sclerosis Clinical Research and Staff Physiatrist, Barrow Neurology Clinics, St Joseph's Hospital and Medical Center; Investigator for Barrow Neurology Clinics; Director, NARCOMS Project for Consortium of MS Centers
Denise I Campagnolo, MD, MS is a member of the following medical societies: Alpha Omega Alpha, American Association of Neuromuscular and Electrodiagnostic Medicine, American Paraplegia Society, Association of Academic Physiatrists, and Consortium of Multiple Sclerosis Centers
Disclosure: Teva Neuroscience Honoraria Speaking and teaching; Serono-Pfizer Honoraria Speaking and teaching; Genzyme Corporation Grant/research funds investigator; Biogen Idec Grant/research funds investigator; Genentech, Inc Grant/research funds investigator; Eli Lilly & Company Grant/research funds Novaritis; Novaritis  Novaritis; MSDx LLC Grant/research funds investigator; BioMS Technology Corp Grant/research funds investigator; Avanir Pharmaceuticals Grant/research funds investigator

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.